These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36422737)

  • 1. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
    Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
    Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum-based chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis.
    Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A
    Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.
    Saleh RR; Nadler MB; Desnoyers A; Meti N; Fazelzad R; Amir E
    Cancer Treat Rev; 2021 Nov; 100():102283. PubMed ID: 34530283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials.
    Xie K; Ren X; Hong X; Zhu S; Wang D; Ye X; Ren X
    Bioengineered; 2022 Jun; 13(6):14827-14839. PubMed ID: 36278891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
    Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
    Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis.
    Lin YY; Gao HF; Yang X; Zhu T; Zheng XX; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K
    Breast; 2022 Dec; 66():126-135. PubMed ID: 36265208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis.
    Petrelli F; Ghidini A; Rea C; Parati MC; Borgonovo K; Ghidini M; Ruatta F; Zaniboni A; Luciani A; Garrone O; Tomasello G
    Curr Probl Cancer; 2024 Jun; 50():101096. PubMed ID: 38608530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
    Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
    BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
    Liu Z; Li J; Zhao F; Ren D; Li Z; Chen Y; Huang S; Liu Z; Zhao Y; Wang M; Li H; Xu Z; Shen G; Zhao J
    BMC Cancer; 2024 Apr; 24(1):440. PubMed ID: 38594636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
    Fasching PA; Hein A; Kolberg HC; Häberle L; Uhrig S; Rübner M; Belleville E; Hack CC; Fehm TN; Janni W; Hartmann A; Erber R; Theuser AK; Brucker SY; Hartkopf AD; Untch M
    Eur J Cancer; 2023 May; 184():1-9. PubMed ID: 36871424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.
    Williams TM; Schneeweiss A; Jackisch C; Shen C; Weber KE; Fasching PA; Denkert C; Furlanetto J; Heinmöller E; Schmatloch S; Karn T; Szeto CW; van Mackelenbergh MT; Nekljudova V; Stickeler E; Soon-Shiong P; Schem C; Mairinger T; Müller V; Marme F; Untch M; Loibl S
    Clin Cancer Res; 2023 Sep; 29(17):3384-3394. PubMed ID: 37432976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
    Xiu M; Zhang P; Wang X; Fan Y; Li Q; Li Q; Wang J; Dong L; Luo Y; Yuan P; Ma F; Xu B
    Int J Cancer; 2022 Aug; 151(4):578-589. PubMed ID: 35403702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.